A Prospective Randomized Open-label Phase 4 Study of the Immunology and Safety of Maternal RSV Vaccination (ABRYSVOTM) Infant Nirsevimab (BEYFORTUSTM) Immunization or Both Products During the First Year of Life

Go Back to All Clinical Trials

A Prospective Randomized Open-label Phase 4 Study of the Immunology and Safety of Maternal RSV Vaccination (ABRYSVOTM) Infant Nirsevimab (BEYFORTUSTM) Immunization or Both Products During the First Year of Life

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Respiratory Syncytial Virus
Age: Between 0 Year(s) - 45 Year(s)
Gender: Male or Female

Other Inclusion Criteria:
1. 18-45 years old
2. Pregnant with one baby
3. Willing for themselves and their baby to receive the FDA-approved products

You may not be eligible for this study if the following are true:

1. Previous severe allergic reaction to a vaccine
2. Immunocompromised status
3. Condition that may prevent you from receiving injections
4. Current pregnancy that is complicated by uncontrolled hypertension, pre-eclampsia or eclampsia
5. Plan to store cord blood
6. Previous receipt of ABRYSVO^TM or other approved or investigational RSV vaccines.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies